PHATHOM PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 345.28 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.50K shares, a 99.96% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 343.78K shares, a 63.97% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 267.36K shares, a 566.33% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 55.75K shares, a 209.72% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 4.82M shares, a 111.33% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.28M shares, a 54.76% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.47M shares, a 15.33% decline from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.74M shares, a 0.97% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 345.28K shares 10-Q · filed 2026-07-30 | 612.64K shares derived: sum of 3 quarters · filed 2026-07-30 | 668.39K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 343.78K shares 10-Q · filed 2026-04-30 | 611.14K shares derived: sum of 2 quarters · filed 2026-04-30 | 666.89K shares derived: sum of 3 quarters · filed 2026-04-30 | 4.21M shares derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-12-31 | 267.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 323.11K shares derived: sum of 2 quarters · filed 2026-02-26 | 3.87M shares derived: sum of 3 quarters · filed 2026-02-26 | 4.82M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 55.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | 3.60M shares derived: sum of 2 quarters · filed 2025-10-30 | 4.56M shares 10-Q · filed 2025-10-30 | 4.60M shares derived: sum of 4 quarters · filed 2025-10-30 |
| 2025-06-30 | 3.55M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 4.50M shares 10-Q · filed 2025-08-07 | 4.54M shares derived: sum of 3 quarters · filed 2025-08-07 | 4.56M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 954.08K shares 10-Q · filed 2025-05-01 | 994.20K shares derived: sum of 2 quarters · filed 2025-05-01 | 1.01M shares derived: sum of 3 quarters · filed 2025-05-01 | 1.37M shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 40.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 58.13K shares derived: sum of 2 quarters · filed 2025-03-06 | 414.13K shares derived: sum of 3 quarters · filed 2025-03-06 | 2.28M shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 18.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 374.00K shares derived: sum of 2 quarters · filed 2024-11-07 | 2.24M shares 10-Q · filed 2024-11-07 | 2.55M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 356.00K shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | 2.22M shares 10-Q · filed 2024-08-08 | 2.53M shares derived: sum of 3 quarters · filed 2024-08-08 | 2.55M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.87M shares 10-Q/A · filed 2024-06-14 | 2.17M shares derived: sum of 2 quarters · filed 2024-06-14 | 2.19M shares derived: sum of 3 quarters · filed 2024-06-14 | 2.30M shares derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-12-31 | 305.75K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | 326.25K shares derived: sum of 2 quarters · filed 2024-06-14 | 431.25K shares derived: sum of 3 quarters · filed 2024-06-14 | 1.47M shares 10-K/A · filed 2024-06-14 |
| 2023-09-30 | 20.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 125.50K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.17M shares 10-Q · filed 2023-11-09 | 1.22M shares derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-06-30 | 105.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.15M shares 10-Q · filed 2023-08-10 | 1.20M shares derived: sum of 3 quarters · filed 2024-06-14 | 1.37M shares derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-03-31 | 1.04M shares 10-Q · filed 2023-05-10 | 1.09M shares derived: sum of 2 quarters · filed 2024-06-14 | 1.27M shares derived: sum of 3 quarters · filed 2024-06-14 | 1.55M shares derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | 50.00K shares derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-06-14 | 221.63K shares derived: sum of 2 quarters · filed 2024-06-14 | 503.51K shares derived: sum of 3 quarters · filed 2024-06-14 | 1.74M shares 10-K/A · filed 2024-06-14 |
| 2022-09-30 | 171.63K shares derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | 453.51K shares derived: sum of 2 quarters · filed 2022-11-09 | 1.69M shares 10-Q/A · filed 2022-11-09 | 1.85M shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 281.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | 1.52M shares 10-Q · filed 2022-08-02 | 1.68M shares derived: sum of 3 quarters · filed 2022-08-02 | 1.73M shares derived: sum of 4 quarters · filed 2022-08-02 |
| 2022-03-31 | 1.24M shares 10-Q · filed 2022-05-10 | 1.40M shares derived: sum of 2 quarters · filed 2022-05-10 | 1.45M shares derived: sum of 3 quarters · filed 2022-05-10 | 1.60M shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 157.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 213.75K shares derived: sum of 2 quarters · filed 2022-03-01 | 366.50K shares derived: sum of 3 quarters · filed 2022-03-01 | 1.73M shares 10-K · filed 2022-03-01 |
| 2021-09-30 | 56.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 209.50K shares derived: sum of 2 quarters · filed 2021-11-08 | 1.57M shares 10-Q · filed 2021-11-08 | 1.81M shares derived: sum of 4 quarters · filed 2021-11-08 |
| 2021-06-30 | 152.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 1.51M shares 10-Q · filed 2021-08-10 | 1.75M shares derived: sum of 3 quarters · filed 2021-08-10 | 2.61M shares derived: sum of 4 quarters · filed 2021-08-10 |
| 2021-03-31 | 1.36M shares 10-Q · filed 2021-05-11 | 1.60M shares derived: sum of 2 quarters · filed 2021-05-11 | 2.46M shares derived: sum of 3 quarters · filed 2021-05-11 | 2.60M shares derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | 241.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | 1.10M shares derived: sum of 2 quarters · filed 2021-03-30 | 1.24M shares derived: sum of 3 quarters · filed 2021-03-30 | 1.38M shares 10-K · filed 2021-03-30 |
| 2020-09-30 | 858.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 1.00M shares derived: sum of 2 quarters · filed 2020-11-10 | 1.13M shares 10-Q · filed 2020-11-10 | 1.13M shares derived: sum of 4 quarters · filed 2020-11-10 |
| 2020-06-30 | 142.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 276.73K shares 10-Q · filed 2020-08-06 | 276.73K shares derived: sum of 3 quarters · filed 2020-08-06 | |
| 2020-03-31 | 134.23K shares 10-Q · filed 2020-05-12 | 134.23K shares derived: sum of 2 quarters · filed 2020-05-12 | ||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | 1.40M shares 10-K · filed 2020-03-19 | ||
| 2019-09-30 | 1.40M shares 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |